Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 17/20 | 0.50 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.43 |
| ▸ | CLK2 | P49760 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.42 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22568713 | 0.96 | KIT (0.49) | KITTBK1CLK2DYRK1AAURKA | |
| SCHEMBL20928276 | 0.94 | TBK1 (0.51) | KITTBK1 | |
| SCHEMBL22568740 | 0.92 | KIT (0.46) | KITTBK1CLK2DYRK1AAURKA | |
| SCHEMBL22568644 | 0.92 | KIT (0.46) | KITTBK1CLK2DYRK1AAURKA | |
| SCHEMBL22568666 | 0.91 | KIT (0.47) | KITTBK1CLK2DYRK1AAURKA | |
| SCHEMBL20928277 | 0.91 | KIT (0.46) | KITTBK1CLK2DYRK1AAURKA | |
| SCHEMBL20927825 | 0.91 | KIT (0.46) | KITTBK1CLK2DYRK1AAURKA | |
| SCHEMBL20927822 | 0.91 | KIT (0.47) | KITTBK1CLK2DYRK1AAURKA | |
| SCHEMBL20928152 | 0.91 | TBK1 (0.48) | KITTBK1 | |
| SCHEMBL22568750 | 0.91 | KIT (0.47) | KITTBK1CLK2DYRK1AAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236086-B2 | Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase | BLUEPRINT MEDICINES CORPORATION (US) | 2022-02-01 | — | — | US | disclosed |
| US-20200331908-A1 | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION | 2020-10-22 | — | — | US | disclosed |
| WO-2019079649-A1 | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION (US) | 2019-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236086-B2 | Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase | ALK, ACVR1, ACVR2A | KIT 318/4885TBK1 397/4885CLK2 787/4885 |
| US-20200331908-A1 | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | ALK, ACVR1, ACVR2A | KIT 318/4885TBK1 397/4885CLK2 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.